Clinical trial · Interventional
Feasibility of Ambulatory Talc. Pleurodesis
Can Talc Pleurodesis for Malignant Pleural Effusion be Performed on an Ambulatory Basis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignancy | Malignant Neoplasm | ALIAS | 0.90 |
| Malignant Pleural Effusion | — | UNRESOLVED | — |
| Palliative Care | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ambulatory chest drain and talc pleurodesis | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- outpatient drain and talc pleurodesis
- description
- Patients enrolled to the trial will have a chest drain inserted and we will aim to drain to dryness and instill medical grade talc as described in the protocol
- interventionNames
- Procedure: ambulatory chest drain and talc pleurodesis
Primary outcomes (1)
- measure
- Success rate of delivery of the ambulatory pleruodesis protocol
- timeFrame
- 5 days
- description
- Can the investigators successfully deliver the described ambulatory pleruodesis protocol within the 5 day time frame and what is the success rate of the protocol delivery.
Secondary outcomes (2)
- measure
- Patient satisfaction / Patient related outcome measurement
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Malignant pleural effusion * Life expectancy \>30 days * WHO PS 1-2 (3 if due to dyspnoea) Exclusion Criteria: * Previous failed pleurodesis (on affected side) * Known non-expansile lung
References
Publications (0)
Data not yet available